Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
This paper reports the pivotal global phase 2 ELIANA trial of tisagenlecleucel, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. It demonstrated high rates of durable remission and supported the first FDA approval of a CAR-T cell therapy. The study also characterized the safety profile, including cytokine release syndrome.